At the end of December 2021, an updated version of the National Plan to Address Alzheimer’s Disease was published to add an additional goal to “accelerate action to promote healthy aging and reduce risk factors for Alzheimer’s Disease.”
In 2011, the National Alzheimer’s Project Act (NAPA) (Public Law 111-375) was signed into law and requires the Secretary of the U.S. Department of Health and Human Services (HHS) to establish the National Alzheimer’s Project to create and maintain an integrated national plan to overcome Alzheimer’s disease.
On December 27, 2021, a ninth update to the national plan was published and included the following two action items related to increasing access to hearing aids in recognition of linkage between untreated hearing loss and dementia.
- (NEW) Action 6.B.2: Increase access to hearing aids for individuals with hearing loss.
Lead Agency: Food and Drug Administration (FDA).
Hearing loss has been identified as a risk factor for Alzheimer’s Disease/Alzheimer’s Disease Related Dementias (AD/ADRD), and recent research has demonstrated that hearing aid use is associated with reduced dementia risk. Hearing aids are often expensive, making them inaccessible to many individuals who could benefit.
- (NEW) Action 6.E.3: Reduce financial barriers to hearing aids for individuals with hearing loss.
The Academy has been actively engaged on this topic and is a member of the UsAgainstAlzheimer’s coalition—a group comprised of many organizations promoting healthy aging, equity, and brain health.
Recent Posts
How Do Animals Perceive Music?
Music can be defined as vocal, instrumental, or mechanical sounds, with rhythm, melody or harmony, and often, an expression of human emotion. Music can transcend…
‘Eye’ on Health: AI Detects Dizziness and Balance Disorders Remotely
Interesting research led by audiologist Ali Danesh, PhD, at Florida Atlantic University (FAU) helped develop a novel, proof-of-concept tool to help identify nystagmus using a…
Rizatriptan vs. Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial
Jeffrey Staab, MD, and colleagues studied the effectiveness of rizatriptan as a treatment option for vestibular migraine. Their research included 134 patients between the ages of…